| Part ? Bioinformatics analysis of pancreatic diseasesObjective: Our early proteomics screening of differentially expressed proteins between pancreatic cancer patients and benign pancreatic tumors,and chronic pancreatitis and Healthy pancreatic tissues.To explore the pathogenesis of pancreatic cancer and provide guidance for the genetic diagnosis and treatment of pancreatic cancer.Methods: Based on the proteomics analysis of the research group,the nonquantitative proteins were screened out in conjunction with the Uni Prot database.The R software was used to analyze GO and Pathway of the differential proteins in each group,and the PPI network was edited with the STRING database.Cytoscape software was used to perform module analysis,and the protein Z-score was calculated.Results: 3927 matching proteins screened from pancreatic diseases.There are 258 differential proteins in the pancreatic cancer group,consist of upregulated proteins by 203 and downregulated proteins by 55.The functional genes are involved in 41 BP,39 CC,and 26 MF.In the benign pancreatic tumor group,there are 72 differential proteins,consist of upregulated proteins by 60,downregulated proteins by 12,and the functional genes involved in 36 BP,13 CC,and 21 MF.The chronic pancreatitis group has 205 differential proteins,consist of 161 up-regulated proteins,44 downregulated proteins involved in 189 BP,65 CC,and 44 MF.Conclusion: In this paper,we search for proteins related to pancreatic diseases from the perspective of bioinformatics,identify the differential expression and functional characteristics of these pancreatic diseases at the molecular level,and bring dependable evidence for elucidating the mechanism of pancreatic diseases.Part ? Expression of BCLAF1 in pancreatic ductal adenocarcinomaand its clinical significanceObjective: To explore the expression level and clinical significance of BCLAF1 protein in pancreatic ductal adenocarcinoma(PDAC).Methods: Methods: Immunohistochemistry was used to detect the expression of BCLAF1 protein in 67 pairs of PDAC and paraffin sections of paracancerous tissues.Real-time quantitative PCR(q RT-PCR)and Western blot were used to detect the expression levels of BCLAF1 protein in 8 matched PDACs and adjacent tissues.After knocking down BCLAF1 expression in CFPAC-1 cells,the invasion potential of CFPAC-1 cells was noticed by Transwell invasion experiment,and the proliferation of CFPAC-1 cells was noticed by CCK-8 method in each group.Results: The results of immunohistochemistry showed that BCLAF1 was mainly expressed in the nucleus of PDAC cells.66 cases(80.59%)were positive for BCLAF1 in PDAC group,which was higher than that in adjacent tissues(35.82%).Western blot results showed that the content of BCLAF1 protein in PDAC was higher than that in adjacent tissues,and the difference was statistically significant(P <0.001).The knockdown of BCLAF1 expression in pancreatic ductal adenocarcinoma cells significantly inhibited the invasion and migration of pancreatic cells,also suppressed the proliferation of CFPAC-1 cells simultaneously.The expression level of BCLAF1 in pancreatic ductal adenocarcinoma was significantly correlated with clinical tumor characteristics such as tumor size,TNM stage,lymph node metastasis,clinical stage,and prognosis.Kaplan-Meier survival analysis showed that the high expression survival time of BCLAF1 was significantly lower than that of BCLAF1(?~2 = 17.419,P <0.01).Multivariate analysis of COX regression showed that BCLAF1 and TNM staging were independent factors influencing the prognosis of pancreatic cancer.Conclusion: The expression level of BCLAF1 in pancreatic ductaladenocarcinoma tissues is significantly related to clinical biological characteristics such as tumor size,Peripancreatic lymph node metastasis,and prognosis,etc.Its detection contributes to the early diagnosis and prognosis assessment of pancreatic ductal adenocarcinoma.It can be seen that knocking down the BCLAF1 expression level obviously restrain the Characteristics of CFPAC-1 cells. |
PDF Full Text Request